Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 2/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31291729 | 0.80 | NCOA1 (0.43) | SLC6A4SIGMAR1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL31291636 | 0.79 | SLC6A4 (0.56) | SLC6A4SIGMAR1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL31291629 | 0.79 | SLC6A4 (0.56) | SLC6A4SIGMAR1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL31291768 | 0.77 | SIGMAR1 (0.53) | SLC6A4SIGMAR1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL31291638 | 0.77 | SIGMAR1 (0.53) | SLC6A4SIGMAR1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL31291705 | 0.75 | MAPKAPK2 (0.41) | SLC6A4HTR2AHTR2CHTR2B | |
| SCHEMBL31291696 | 0.73 | FEN1 (0.35) | SLC6A4KCNH2HTR2AHTR2C | |
| SCHEMBL31291706 | 0.71 | MDH2 (0.41) | SLC6A4 | |
| SCHEMBL31622890 | 0.69 | CA12 (0.39) | — | |
| SCHEMBL31622891 | 0.69 | CA12 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376116-A1 | IBOGAINE AND NORIBOGAINE ANALOGS AND METHODS OF USE | DALRIADA DRUG DISCOVERY, INC. (CA) | 2024-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376116-A1 | IBOGAINE AND NORIBOGAINE ANALOGS AND METHODS OF USE | OPRM1, OPRD1, SIGMAR1 | SLC6A4 374/4885SIGMAR1 3/4885CHRNB2 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.